How EU Regulation Shifts Are Shaping Cibus’ Biofragrance Revenue in Q2 2025

Europe’s policy pivot on gene-edited plants is beginning to reshape commercial timelines for agricultural biotech. For Cibus, those changes are landing at an opportune moment, giving its fermentation-based fragrance program a clearer path to market. The result: Biofragrance Revenue looks better supported in Q2 2025 and positioned for steadier growth over the next few quarters.